FY2026 Earnings Forecast for EWTX Issued By HC Wainwright

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Research analysts at HC Wainwright issued their FY2026 EPS estimates for Edgewise Therapeutics in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst L. Egana-Gorrono forecasts that the company will post earnings per share of ($2.02) for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ FY2027 earnings at ($2.46) EPS, FY2028 earnings at ($2.05) EPS, FY2029 earnings at ($1.11) EPS and FY2030 earnings at $2.30 EPS.

Several other research firms have also recently weighed in on EWTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Wednesday, January 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Edgewise Therapeutics in a research report on Monday, February 9th. Evercore reiterated an “outperform” rating and issued a $45.00 price objective on shares of Edgewise Therapeutics in a report on Thursday. Wedbush decreased their target price on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a research report on Friday, November 7th. Finally, Royal Bank Of Canada boosted their price target on shares of Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Edgewise Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $36.36.

Edgewise Therapeutics Trading Up 2.6%

EWTX stock opened at $30.44 on Monday. The stock has a 50-day moving average price of $27.62 and a two-hundred day moving average price of $21.27. Edgewise Therapeutics has a 1 year low of $10.60 and a 1 year high of $31.82. The stock has a market cap of $3.27 billion, a PE ratio of -18.67 and a beta of 0.26.

Edgewise Therapeutics (NASDAQ:EWTX) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04).

Insider Buying and Selling

In other news, Director Badreddin Edris sold 115,471 shares of Edgewise Therapeutics stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $29.44, for a total value of $3,399,466.24. Following the completion of the transaction, the director owned 19,820 shares of the company’s stock, valued at $583,500.80. This trade represents a 85.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 23.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Edgewise Therapeutics

A number of institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Edgewise Therapeutics by 6.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,776 shares of the company’s stock valued at $963,000 after buying an additional 2,463 shares during the period. Jones Financial Companies Lllp acquired a new position in shares of Edgewise Therapeutics during the 1st quarter worth approximately $47,000. Goldman Sachs Group Inc. raised its stake in Edgewise Therapeutics by 5.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 366,644 shares of the company’s stock valued at $8,066,000 after acquiring an additional 19,753 shares during the period. Strs Ohio acquired a new stake in Edgewise Therapeutics during the 1st quarter valued at $84,000. Finally, Teacher Retirement System of Texas boosted its position in Edgewise Therapeutics by 10.7% during the second quarter. Teacher Retirement System of Texas now owns 12,646 shares of the company’s stock worth $166,000 after purchasing an additional 1,225 shares during the period.

Key Headlines Impacting Edgewise Therapeutics

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: Multiple near‑term clinical catalysts could drive upside: management flagged CIRRUS‑HCM 12‑week data for EDG‑7500 and Phase 1 healthy‑adult data for EDG‑15400 (with planned heart‑failure studies) expected in H1 2026, and pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy anticipated in Q4 2026. These readouts materially de‑risk the pipeline and are likely the main reason investors are buying the stock. PR Newswire: Q4 & Full Year 2025 Results
• Positive Sentiment: Company increased R&D investment in Q4, signaling management is funding those near‑term trials and pivotal work — a positive for long‑term value creation if the upcoming readouts are favorable. BizWest: R&D boost
• Neutral Sentiment: Analyst modeling: HC Wainwright published quarterly EPS forecasts for 2026 (Q1 -$0.43, Q2 -$0.47, Q3 -$0.51, Q4 -$0.60; full‑year -$1.45). These estimates reinforce expectations of continued operating losses as the company advances trials; they provide a near‑term earnings framework but don’t change the pipeline narrative. MarketBeat: HC Wainwright estimates
• Neutral Sentiment: Valuation discussion: recent coverage (e.g., Yahoo Finance) examines EWTX’s strong multi‑year returns and recent momentum, useful for investors assessing whether current share price already reflects upcoming catalysts. Yahoo Finance: Valuation piece
• Negative Sentiment: Q4 earnings miss and near‑term financial drag: Edgewise reported EPS of ($0.47) for the quarter, missing the consensus ($0.43). The combination of the miss and higher R&D spend increases short‑term risk and means more funding will likely be required before positive cash flow. Press Release: Q4 Results

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.